Eyevance Pharma acquires worldwide rights to Nexagon

3 October 2018

US ocular health company Eyevance Pharmaceuticals has entered into a worldwide licensing agreement with OcuNexus Therapeutics for Nexagon, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) non-responsive to standard of care.

Nexagon is a first in class unmodified antisense oligodeoxynucleotide that inhibits a cell membrane hemichannel forming protein, connexin43 (Cx43). Cx43 is over-expressed after acute injury or in chronic disease states leading to pathological prematurely open hemichannels, allowing ATP to enter the extracellular space.

As part of its plan to develop Nexagon, Eyevance is currently funding a pivotal clinical trial with an anticipated start date of first-quarter 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK